loading page

Azacitidine and venetoclax for post-transplant relapse of CBFA2T3/GLIS2 childhood acute myeloid leukaemia
  • +1
  • AVIJEET MISHRA,
  • Khushnuma Mullanfiroze,
  • Robert Chiesa,
  • Ajay Vora
AVIJEET MISHRA
Great Ormond Street Hospital For Children NHS Trust
Author Profile
Khushnuma Mullanfiroze
Great Ormond Street Hospital For Children NHS Trust
Author Profile
Robert Chiesa
Great Ormond Street Hospital For Children NHS Trust
Author Profile
Ajay Vora
Great Ormond Street Hospital For Children NHS Trust

Corresponding Author:[email protected]

Author Profile

Abstract

We report a case of 17-month-old girl who was diagnosed with CBFA2T3/GLIS2 rearranged AMKL.Three months after a TCR αβ-CD19 depleted haploidentical HSCT she presented with decreasing donor chimaerism, positive flow MRD(0.2%) and more than two log rise in CBFA2T3/GLIS2 transcripts. After one cycle of azacitidine and venetoclax she achieved molecular remission and donor chimaerism reverted to 100%. This is the first case report of a CBFA2T3/GLIS2 rearranged AMKL responding to this combination. This strategy, if proven to be effective in a larger cohort, could be used to treat relapse after HSCT in this high risk group of patients.